Senti Biosciences Inc (NASDAQ:SNTI) surges post CEO’s participation on Gene Regulation 

Stock of Senti Biosciences (NASDAQ:SNTI) last traded at $5.14 USD, a gain of +2.64 (105.60%). More than 68,212,695 shares exchanged hands compared to an average daily volume of just over 3M shares. The company has a 52 week high of more than 10$ suggesting quite a bit of room for the stock to surge if retail traders decide to fuel the fire.

So why did SNTI surge today ?

Let’s start by taking a look at what exactly does this biotech company encompass. SNTI claims itself to be building a synthetic biology platform that may enable us to program next-generation cell and gene therapies with what we refer to as Gene Circuits. These Gene Circuits, which are created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We aim to design Gene Circuits to improve the intelligence of cell and gene therapies in order to enhance their therapeutic effectiveness, precision, and durability against a broad range of diseases that conventional medicines do not readily address.

Earlier, the company had announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman, and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Chardan’s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, at 1:30 PM ET. Tim Lu was suppose to also participate in a panel on Gene Regulation on Tuesday, October 4, 2022, at 9:30 AM ET.

So does that mean that the presentation was appreciated by others in the field and potential investors may have caught wind of SNTI’s technology ? Apparently so, considering that no new update has yet been released by the company our guess is good as yours.

SNTI Chart: Credit: StockCharts